IMMUNITYBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.4 USD | -2.67% |
|
+1.69% | +67.33% |
Presenter SpeechR.A. McDonough;JPMorgan;Analyst (Analysts)Great. Hi, I'm R.A. McDonough from J...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.4
USD
Average target price
7.5
USD
Spread / Average Target
-10.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +67.33% | 5.97B | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
- Stock Market
- Equities
- IBRX Stock
- News ImmunityBio, Inc.
- Transcript : NantKwest, Inc. Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-14-2020 11
